Biognosys’ proprietary P2 Plasma Enrichment System enables plasma proteome profiling with unprecedented depth and throughput, both as contract research and in-house via licensing By offering the ...

Tandem Mass Tag™ (TMT™) reagents enable simultaneous identification and relative quantification of thousands of proteins from many samples in a single LC-MS/MS acquisition on Thermo Scientific™ ...

New nanoElute 2 features nano-LC advances, supports automated single cell sample preparation from label-free ProteoCHIP on CellenONE platform MetaboScape® 2023 advances fluxomics applications and ion ...

SCHLIEREN, Switzerland and BILLERICA, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Biognosys AG and Bruker Corporation (Nasdaq: BRKR) today announced a strategic partnership, in which Bruker has made a ...

Proteomics, which is generally defined as the characterization of the complete protein complement of a cell, tissue, or organism (a proteome), has moved to the forefront of "big science" now that the ...

Proteomics and genomics share the common goal of characterizing biological systems, yet they differ fundamentally in their molecular targets, analytical challenges and interpretive value. Genomics ...

While the vast majority of approved pharmaceuticals target proteins, knowledge of the full complement of proteins that are acted on by drugs, or are potentially druggable, remains incomplete.

Proteomics has become an essential area in medical research, propelled by the ability to quantitatively assess proteins on a large scale using high-throughput technologies. These technologies have ...

The 21st century has witnessed remarkable advances in molecular biology. Not only are these advances transforming our understanding of life’s most fundamental processes, but they are also starting to ...

New strategic partnership aims to broaden access to Biognosys’ leading CRO services and Spectronaut® software tools for unbiased proteomics and epiproteomics Expected to benefit proteomics research, ...